Bristol-Myers Squibb Co.

NYSE:BMY   3:59:56 PM EDT
-0.52 (-0.73%)

U.S. FDA Approves Sotyktu, Oral Treatment For Adults With Moderate-To-Severe Plaque Psoriasis

Published: 09/10/2022 09:24 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults With Moderate-to-severe Plaque Psoriasis.
Sotyktu Has a Well-demonstrated Safety and Tolerability Profile Based on the Poetyk Pso Clinical Trials.
Approval is Based on Results From the Pivotal Phase 3 Poetyk Pso-1 and Poetyk Pso-2 Clinical Trials.